FC
Farallon Capital Management, L.L.C. disclosed a 7.3% stake in BBIO
Farallon Capital Management, L.L.C. reported owning 7.3% of BridgeBio Pharma, Inc. (BBIO) (14,247,000 shares) in a Schedule 13G filed Nov 12, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Nov 12, 2026
- Source
- Schedule 13G